Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Creative Planning

Posted by on Oct 17th, 2023

Creative Planning decreased its position in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 6.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,978 shares of the biopharmaceutical company’s stock after selling 509 shares during the period. Creative Planning’s holdings in Horizon Therapeutics Public were worth $718,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. TFC Financial Management Inc. acquired a new position in shares of Horizon Therapeutics Public in the first quarter worth $25,000. Global Retirement Partners LLC increased its stake in Horizon Therapeutics Public by 156.4% during the second quarter. Global Retirement Partners LLC now owns 241 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 147 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in Horizon Therapeutics Public during the first quarter worth about $31,000. Samalin Investment Counsel LLC acquired a new stake in Horizon Therapeutics Public during the first quarter worth about $41,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Horizon Therapeutics Public by 209.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 433 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 293 shares during the period. Institutional investors and hedge funds own 80.37% of the company’s stock.

Horizon Therapeutics Public Price Performance

HZNP stock opened at $116.30 on Tuesday. The firm’s 50-day moving average price is $112.11 and its two-hundred day moving average price is $107.18. Horizon Therapeutics Public Limited has a 12-month low of $60.03 and a 12-month high of $116.38. The stock has a market capitalization of $26.63 billion, a price-to-earnings ratio of 62.19, a PEG ratio of 3.96 and a beta of 1.03. The company has a current ratio of 4.27, a quick ratio of 4.09 and a debt-to-equity ratio of 0.48.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Free Report) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.08. The firm had revenue of $945.00 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a return on equity of 20.46%. Horizon Therapeutics Public’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.07 earnings per share. As a group, equities analysts predict that Horizon Therapeutics Public Limited will post 4.19 earnings per share for the current year.

Analysts Set New Price Targets

HZNP has been the subject of several analyst reports. Jefferies Financial Group downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. StockNews.com started coverage on Horizon Therapeutics Public in a research report on Monday. They issued a “strong-buy” rating for the company. Eight analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $110.71.

Check Out Our Latest Stock Analysis on HZNP

Horizon Therapeutics Public Profile

(Free Report)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.

Featured Stories

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.